6 results about "Acellular scaffold" patented technology

The invention relates to a preparation method and application of acellular extracellular matrix hydrogel for organoid culture, and the method comprises the following steps: step (1): preparing a small intestine acellular scaffold: sequentially putting pig small intestines without adipose tissues into a first solution, a second solution, a third solution and a fourth solution, stirring, and freezing and freeze-drying to obtain the small intestine acellular scaffold; step (2): preparing small intestine acellular matrix hydrogel, cutting a small intestine acellular scaffold into small pieces or grinding the small intestine acellular scaffold into powder, preparing a small intestine acellular scaffold solution with a hydrochloric acid solution and a pepsase solution, centrifuging, adding a PBS solution to terminate digestion, and adjusting the pH value to 6.0-8.0 to obtain solution state small intestine acellular matrix hydrogel; and gelling the solution-state small intestine extracellular matrix hydrogel at the temperature of 37 DEG C for 20-60 minutes to obtain the gel-state small intestine extracellular matrix hydrogel which is used for culturing alimentary canal organs.

The invention relates to a decellularized scaffold composite dynamic hydrogel material which comprises an interpenetrating network structure formed by a decellularized scaffold and dynamic cross-linked hydrogel, and the dynamic cross-linked hydrogel is formed by cross-linking initiated by hydrophobic group modified hyaluronic acid and cross-linked group modified cyclodextrin. The dynamic crosslinking hydrogel further comprises hydrogel formed by crosslinking initiated by gelatin or crosslinking group modified glycosaminoglycan. The invention also relates to a preparation method of the composite material. The preparation method comprises the following steps: preparing a pre-gel solution from the hydrophobic group modified hyaluronic acid, the crosslinking group modified cyclodextrin and the crosslinking initiator; and dripping the pre-gel solution on the surface of the decellularized scaffold, and initiating cross-linking to obtain the hydrogel-decellularized scaffold composite material. The decellularized scaffold composite dynamic hydrogel material satisfies three characteristics of mechanical properties, biological adaptation degradability and structural dynamic heterogeneity, is a scaffold material better imitating an extracellular matrix, and has an application prospect in the field of tissue repair.

The present disclosure provides a bioengineered kidney construction method based on organoids and acellular scaffolds, which comprises first injecting pro-vascular stem cells into a kidney acellular scaffold material, and then culturing for several days through fluid circulation perfusion, and then injecting kidney organoids (KIO) into the scaffold material for perfusion culture after the kidney acellular scaffold material is recellularized. The bioengineered kidney obtained by the method of the present disclosure can be used as a graft for replacing kidney function. The present disclosure also provides a kidney organoid culture and expansion method, and the organoids obtained by the method contain not only kidney parenchymal cells such as glomerular cells and renal tubular cells, but also blood vessels and immune cells, which provides a good source of kidney parenchymal cells for the preparation of tissue-engineered kidneys.

This invention relates to the field of biomedical materials technology, providing a heparinized dual-growth factor recellularized adipose tissue decellularized scaffold material, its preparation method, and its applications. The preparation method includes: decellularizing adipose tissue to obtain adipose tissue decellularized scaffold; heparinizing the scaffold to obtain a heparinized adipose tissue decellularized scaffold; loading hepatocyte growth factor and vascular endothelial cell growth factor onto the scaffold to obtain a heparinized dual-growth factor adipose tissue decellularized scaffold; seeding induced pluripotent stem cell-derived hepatocytes onto the scaffold, and culturing to obtain a heparinized dual-growth factor recellularized adipose tissue decellularized scaffold (RAT). This invention uses rat inguinal adipose tissue to prepare RAT material, which is low-cost, readily available, has a simple preparation process, and is easy to scale up. The RAT material of this invention can achieve liver tissue damage repair and hepatocyte regeneration, providing a new treatment strategy for acute liver failure.

The application relates to the field of tissue engineering and regenerative medicine, and particularly discloses a cell-extracellular matrix complex for hair follicle regeneration and a preparation method thereof. The complex comprises autologous hair follicle stem cells, a human scalp-derived acellular ECM scaffold, time-sequentially added growth factors and an anti-scarring component. In preparation, the autologous hair follicle stem cells are first induced by BMP4 and TGF-beta 1 in cooperation, then inoculated into the human scalp-derived acellular ECM scaffold, and the complex is constructed under dynamic culture conditions, and VEGF is added to promote vascularization. The complex can efficiently form a structure-intact hair papilla-like tissue, has good biocompatibility, low immunogenicity and anti-scarring characteristics, and is significantly superior to a traditional collagen scaffold system. The application provides a new regeneration treatment strategy with clear clinical transformation prospects for scaleable preparation for androgenetic alopecia and other hair follicle deficiency diseases.

The present invention provides a method of producing a thymic construct suitable for implantation into a subject, the method comprising the steps of: (i) providing a decellularised scaffold; (ii) seeding the decellularised scaffold with thymic epithelial cells having mesenchymal properties; and (iii) culturing the seeded scaffold to produce the construct. The thymic epithelial cells are preferably CD49f + , also VIM + , TE-7 + , and / or CD90 + . The present invention further provides pharmaceutical compositions, uses and therapies using thymic epithelial cells having mesenchymal properties.